Bixiye
QP71-18 Pharmacy Benefit Update - New Drug-Related Step Therapy with Quantity Limit Criteria: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2801 - 2810 ee natiijooyinka 3167
Bixiye
QP69-18 Universal Pharmacy Policy for Minnesota Health Care Programs Subscribers - Morphine Equivalent Dose (MED) Limit Update
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP65-18 Pharmacy Benefit Update - New Drug-Related Prior Authorization with Quantity Limit Criteria: Jynarque (tolvapin)
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP66-18 Pharmacy Benefit Update - New Drug-Related Prior Authorization with Quantity Limit Criteria: Noctiva (desmopressin acetate)
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP67-18 Pharmacy Benefit Exclusion for Alferon N (interferon alpha-n3), Cytovene (ganciclovir), Foscarvir (foscarnet), Prevymis (letermovir), Trogarzo (ibalizu,ab-uiyk), Vistide (cidofovir) and Zovirax (actclovir)
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP72-18 Pharmacy Benefit Update - New Drug-Related Step Therapy with Quantity Limit Criteria: Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP68-18 Site of Care Drug Infusion/Injection Program
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP70-18 Pharmacy Benefit Exclusion for Alferon N (interferon alpha-n3) and Lanoxin (digoxin) Injection for Minnesota Health Care Programs Subscribers
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP64-18 Action Required: Apply for Designation as a Blue Distinction Center for Spine Surgery
Taariikhda barnaamijka Dhaqangalayso Agosto 14, 2018
Bixiye
QP63-18 Action Required: Apply for Designation as a Blue Distinction Center for Knee and Hip Replacement
Taariikhda barnaamijka Dhaqangalayso Agosto 14, 2018